SCHEMBL6534713

SCHEMBL6534713

CCCCc1nc(C(Cl)c2ccc(-c3ccccc3-c3nnn[nH]3)cc2)c(C(=O)O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 3/20 0.39
PPARG P37231 1/20 0.37
AGTR1 P30556 4/20 0.36
AGTR2 P50052 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7050688 0.86 AGTR1 (0.34) BRS3PPARGAGTR1AGTR2
SCHEMBL9205903 0.83 BRS3 (0.43) BRS3AGTR1AGTR2
SCHEMBL7220511 0.80 AGTR1 (0.35) BRS3AGTR1AGTR2
SCHEMBL8741233 0.79 GCGR (0.32) BRS3PPARG
SCHEMBL3118883 0.77 AGTR1 (0.36) AGTR1AGTR2
SCHEMBL7308925 0.76 AGTR1 (0.39) BRS3PPARGAGTR1AGTR2
SCHEMBL7305287 0.75 BRS3 (0.36) BRS3PPARGAGTR1AGTR2
SCHEMBL7307408 0.75 PPARG (0.36) BRS3PPARGAGTR1AGTR2
SCHEMBL6534773 0.74 BRS3 (0.54) BRS3AGTR1AGTR2
SCHEMBL7308392 0.73 AGTR1 (0.42) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0754042-A4 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO INC (US) 2004-06-23 EP claimed
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP claimed
JP-2000508347-A 2000-07-04 JP claimed
EP-0966282-A1 USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE Merck & Co., Inc. (US) 1999-12-29 EP claimed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO claimed
WO-1998030216-A1 USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE MERCK & CO., INC. (US) 1998-07-16 WO claimed
EP-0754042-A1 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO. INC. (US) 1997-01-22 EP claimed
EP-0754042-A4 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO INC (US) 2004-06-23 EP disclosed
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP disclosed
EP-0966282-A1 USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE Merck & Co., Inc. (US) 1999-12-29 EP disclosed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO disclosed
WO-1998030216-A1 USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE MERCK & CO., INC. (US) 1998-07-16 WO disclosed
EP-0754042-A1 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO. INC. (US) 1997-01-22 EP disclosed